132P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC): RATIONALE-307 updated analysis. (December 2022) - Wang, J.; Lu, S.; Yu, X.; Hu, Y.; Zhao, J.; Sun, M.L.; Yu, Y.; Hu, C.; Yang, K.; Song, Y.; Lin, X.; Liang, L.; et al.